Sermorelin Troches – 500 MCG

Product Overview

Sermorelin acetate is a synthetic form of growth hormone–releasing hormone (GHRH), composed of the first 29 amino acids identical to natural human GHRH. It works by stimulating the pituitary gland to naturally produce and release growth hormone (GH).

By increasing endogenous GH secretion, sermorelin can lead to higher levels of insulin-like growth factor-1 (IGF-1), a hormone involved in growth, metabolism, and tissue maintenance. This therapy is primarily used in individuals with documented growth hormone deficiency, such as pediatric patients with impaired growth due to inadequate GH production.

In adults with confirmed GH deficiency, sermorelin may also be considered as a therapeutic option. Its use in individuals without GH deficiency, including for so-called “anti-aging” purposes, is not FDA-approved and remains unproven.

Sermorelin was previously approved in the 1990s for diagnostic and therapeutic use in GH deficiency but was later discontinued for commercial reasons unrelated to safety or effectiveness. Today, it is available through compounding pharmacies upon prescription.

Sermorelin is administered as a subcutaneous injection, typically once daily in the evening, and must be prescribed and monitored by a qualified healthcare provider. Because it stimulates the body’s own GH production rather than supplying synthetic GH, sermorelin may offer a more physiologic approach with a different side-effect profile.

All use should occur under medical supervision with appropriate monitoring.

---

Dosage & Administration

General Dosing Information

Sermorelin dosing is individualized based on age, body weight, clinical condition, and laboratory results. Therapy should be supervised by clinicians experienced in managing growth hormone disorders.

Adults (Therapeutic Use)

A commonly used adult dose ranges from 0.2–0.3 mg, administered subcutaneously once daily at bedtime. Nighttime dosing is intended to align with the body’s natural GH release during sleep. Providers may initiate treatment at the lower end of the range and adjust based on IGF-1 levels and clinical response.

Pediatric Patients

In children with idiopathic GH deficiency, dosing has historically been weight-based at approximately 0.03 mg/kg (30 mcg/kg) once nightly. Growth velocity and IGF-1 levels are monitored, and dose adjustments are made as needed. Response may vary, and alternative therapies may be required if adequate growth is not achieved.

Diagnostic Use

In select endocrine testing, sermorelin may be administered intravenously at 1 mcg/kg to assess pituitary GH reserve. This use is limited to specialized clinical settings and healthcare professionals.

---

Administration Details

• Supplied as a lyophilized powder requiring reconstitution with a prescribed diluent

• Vial should be gently swirled (not shaken) until dissolved

• Administered subcutaneously using an insulin-type syringe

• Injection sites should be rotated to reduce irritation

• Missed doses should not be doubled

• All sharps must be disposed of in approved containers

---

Treatment Duration & Monitoring

Treatment length varies by indication and patient response. Pediatric therapy may continue until growth goals are met or growth plates close. Adult therapy duration depends on symptom improvement and laboratory targets.

Ongoing monitoring typically includes:

• Serum IGF-1 levels

• Growth velocity (children)

• Metabolic markers, glucose levels, thyroid and adrenal function

• Clinical response and tolerance

If adequate response is not observed within 3–6 months, therapy may be adjusted or discontinued.

---

Mechanism of Action

Sermorelin binds to GHRH receptors in the anterior pituitary, promoting the synthesis and pulsatile release of endogenous growth hormone. This increase in GH subsequently stimulates IGF-1 production, primarily by the liver.

Because sermorelin activates the body’s natural regulatory pathways, normal hormonal feedback mechanisms remain intact. This physiologic stimulation may reduce the risk of excessive hormone exposure compared to direct GH administration.

Sermorelin is effective only in patients with functioning pituitary GH-producing cells and will not work in individuals with absent or nonfunctional somatotrophs.

---

Contraindications & Precautions

Sermorelin should not be used in patients with:

• Known hypersensitivity to sermorelin or formulation components

• Active malignancy or untreated cancer

• Intracranial tumors causing GH deficiency

• Uncontrolled hypothyroidism

• Pregnancy or breastfeeding (unless benefits clearly outweigh risks)

Sermorelin is indicated only for patients with documented medical need and is not approved for cosmetic, anti-aging, or performance-enhancing purposes.

---

Drug & Laboratory Interactions

Certain medications may reduce sermorelin’s effectiveness or require monitoring, including:

• High-dose corticosteroids

• Somatostatin analogs

• Unstable thyroid hormone therapy

• Insulin or glucose-lowering agents

Sermorelin may transiently alter laboratory values such as alkaline phosphatase or phosphorus. Healthcare providers and laboratories should be informed of therapy.

---

Adverse Reactions & Side Effects

Common

• Injection-site reactions (redness, swelling, discomfort)

• Headache, flushing, dizziness, nausea, or fatigue

Less Common / Rare

• Hypersensitivity reactions

• Dysphagia or throat tightness

• Transient changes in glucose or thyroid function

Development of low-titer antibodies has been observed but generally does not reduce effectiveness.

Patients should report persistent or concerning symptoms to their healthcare provider.

---

Pregnancy & Breastfeeding

Sermorelin is not recommended during pregnancy or lactation due to limited safety data. Women who are pregnant, breastfeeding, or planning pregnancy should discuss risks thoroughly with their provider.

---

Storage & Handling

• Unreconstituted vials: Store at room temperature (20–25°C), protected from light

• After reconstitution: Refrigerate at 2–8°C and use within the pharmacy-specified beyond-use date

• Do not freeze or expose to heat

• Inspect solution before use; discard if discolored or particulate

• Dispose of sharps properly and follow pharmacy disposal instructions

---

Important Notice

This information is provided for educational purposes only and does not replace medical advice. All dosing and treatment decisions must follow the prescribing healthcare provider’s instructions.